Boehringer Ingelheim and VTU Technology sign manufacturing deal

Boehringer Ingelheim is to augment its manufacturing capabilities via a new partnership with VTU Technology.

The agreement will see VTU Technology provide Boehringer Ingelheim with access to its ready-to-use high expression Pichia system, for use in the development and creation of therapeutic proteins.

This will allow the two organisations to provide their partners and clients with a broader array of contract manufacturing services, with the firms' use of cross-compatible platforms enabling smooth technology transfers.

Professor Dr Rolf Werner, senior vice-president of Boehringer Ingelheim's biopharmaceuticals division, said: "This collaboration will bring a proven high-expression Pichia technology offering us great value and further flexibility in our contract manufacturing business, while complementing our existing scaffold technology platforms."

Dr Michael Koncar, founder and chief executive officer of VTU Technology, added that the alliance will allow it to deliver its technology to a wider customer base.

Last week, Boehringer Ingelheim published new clinical trial data supporting the efficacy of its atrial fibrillation drug Pradaxa.